{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nikitina LE"],"funding":["Kazan Federal University Strategic Academic Leadership Program","Council on grants of the President of the Russian Federation","Russian Science Foundation"],"pagination":["24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8773274"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Platelet aggregation causes various diseases and therefore challenges the development of novel antiaggregatory drugs. In this study, we report the possible mechanism of platelet aggregation suppression by newly synthesized myrtenol-derived monoterpenoids carrying different heteroatoms (sulphur, oxygen, or nitrogen). Despite all tested compounds suppressed the platelet aggregation in vitro, the most significant effect was observed for the S-containing compounds. The molecular docking confirmed the putative interaction of all tested compounds with the platelet's P2Y12 receptor suggesting that the anti-aggregation properties of monoterpenoids are implemented by blocking the P2Y12 function. The calculated binding force depended on heteroatom in monoterpenoids and significantly decreased with t"],"journal":["Bioengineering (Basel, Switzerland)"],"pubmed_title":["Unraveling the Mechanism of Platelet Aggregation Suppression by Monoterpenoids."],"pmcid":["PMC8773274"],"funding_grant_id":["no number","20-64-47014","МК-197.2021.1.3"],"pubmed_authors":["Azizova ZR","Kayumov AR","Nikitina LE","Antina EV","Frolova LL","Klochkov VV","Pavelyev RS","Ksenofontov AA","Rakhmatullin IZ","Ostolopovskaya OV","Bocharov PS","Timerova AF","Kutchin AV","Kiselev SV","Boichuk SV","Galembikova AR","Khelkhal MA","Andriutsa NS","Gilfanov IR"],"additional_accession":[]},"is_claimable":false,"name":"Unraveling the Mechanism of Platelet Aggregation Suppression by Monoterpenoids.","description":"Platelet aggregation causes various diseases and therefore challenges the development of novel antiaggregatory drugs. In this study, we report the possible mechanism of platelet aggregation suppression by newly synthesized myrtenol-derived monoterpenoids carrying different heteroatoms (sulphur, oxygen, or nitrogen). Despite all tested compounds suppressed the platelet aggregation in vitro, the most significant effect was observed for the S-containing compounds. The molecular docking confirmed the putative interaction of all tested compounds with the platelet's P2Y12 receptor suggesting that the anti-aggregation properties of monoterpenoids are implemented by blocking the P2Y12 function. The calculated binding force depended on heteroatom in monoterpenoids and significantly decreased with t","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-21T17:34:46.929Z","creation":"2022-02-11T16:08:00.937Z"},"accession":"S-EPMC8773274","cross_references":{"pubmed":["35049733"],"doi":["10.3390/bioengineering9010024"]}}